Santen Pharmaceutical Co. Ltd. announced the change of position of Akira Kurokawa from Representative Director of the board, President, Chief Executive Officer to Representative Director of the Board, Chairman and Chief Executive Officer. Designation of Shigeo Taniuchi will be changed from Member of the Board, Senior Corporate Officer, Head of Santen EMEA, President of Santen Holdings EU B.V. to Representative Director of the Board, President and Chief Operating Officer. Designation of Takeshi Ito will be changed from Member of the Board, Executive Corporate Officer, Japan Business, Head of Japan Sales & Marketing and Prescription Pharmaceuticals to Member of the Board, Executive Corporate Officer, Japan Business, Head of Japan Sales & Marketing, Prescription Pharmaceuticals. Designation of Akihiro Tsujimura will be changed from Member of the Board, Executive Corporate Officer, Asia and North America Businesses, Head of Asia Division, President & CEO of Santen Inc. to Member of the Board, Executive Corporate Officer, Asia and North America Businesses, Head of Asia Division, President & CEO of Santen Inc. Designation of Masamichi Sato will be changed from Senior Corporate Officer and Chief Compliance Officer (CCO), Head of CSR & Internal Control Division, CEO of Santen Business Services Co., Ltd. to Senior Corporate Officer and Chief Compliance Officer (CCO), Head of CSR & Internal Control Division, CEO of Santen Business Services Co., Ltd. Designation of Naveed Shams will be changed from Senior Corporate Officer and Chief Scientific Officer (CSO), Head of Global Research & Development to Senior Corporate Officer and Chief Scientific Officer (CSO), Head of Global Research & Development. Designation of Atsutoshi Ota will be changed from Senior Corporate Officer, Head of Human Resources Development Division to Senior Corporate Officer, Head of Human Resources Development Division. Designation of Kazuo Koshiji will be changed from Senior Corporate Officer and Chief Financial Officer (CFO), Head of Finance & Administration Division to Senior Corporate Officer, Corporate Administration, Chief Financial Officer (CFO), Head of Finance & Administration Division. Designation of Akio Kimura will be changed from Senior Corporate Officer, Global Product Supply, Head of Manufacturing Division to Senior Corporate Officer, Global Product Supply, Head of Manufacturing Division. Designation of Satoshi Suzuki will be changed from Senior Corporate Officer, Head of Corporate Development Division to Senior Corporate Officer, Head of Corporate Development Division. Designation of Kenji Morishima will be changed from Corporate Officer, Head of Pharmaceutical Technology Development to Corporate Officer, Head of Pharmaceutical Technology Development. Designation of Noriaki Yamamoto will be changed from Corporate Officer and Chief Information Officer (CIO), Head of Information Systems Division to Corporate Officer and Chief Information Officer (CIO), Head of Information Systems Division. Designation of Ye Liu will be changed from Corporate Officer, General Manager, Santen Pharmaceutical (China) Co., Ltd. to Corporate Officer, General Manager, Santen Pharmaceutical (China) Co., Ltd. Designation of Takahiro Morita will be changed from Corporate Officer, Head of Japan Prescription Pharmaceuticals Sales to Corporate Officer, Head of Japan Prescription Pharmaceuticals Sales. Designation of Frank Binder will be changed from Head of Supply Chain Division to Corporate Officer, Head of Supply Chain Division. All the above changes are effective from April 1, 2018.